Skip to Primary Navigation

AstraZeneca faces US class action lawsuit amidst China regulatory probes

The lawsuit claims that UK's largest listed company misled shareholders in connection with investigations by the Chinese government.

Article label: Quick Read

AstraZeneca PLC, the British-Swedish pharmaceutical giant, is facing a securities class action lawsuit in the US. The action alleges that the company misled investors about its business practices in China.

The lawsuit, filed in the US District Court for the Central District of California, claims that AstraZeneca made false and

Get full access, free for a month

Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

What’s included:

  • Every new article, plus our 6,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience